NCT06007937 2026-02-05
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
Memorial Sloan Kettering Cancer Center
Hoosier Cancer Research Network
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano